JPWO2020194052A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020194052A5 JPWO2020194052A5 JP2021556884A JP2021556884A JPWO2020194052A5 JP WO2020194052 A5 JPWO2020194052 A5 JP WO2020194052A5 JP 2021556884 A JP2021556884 A JP 2021556884A JP 2021556884 A JP2021556884 A JP 2021556884A JP WO2020194052 A5 JPWO2020194052 A5 JP WO2020194052A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- dose
- metformin
- inhibitor
- sitagliptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 71
- 229960003105 metformin Drugs 0.000 claims 36
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 36
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 24
- 229960004034 sitagliptin Drugs 0.000 claims 24
- 239000003472 antidiabetic agent Substances 0.000 claims 23
- 206010012601 diabetes mellitus Diseases 0.000 claims 19
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 18
- 239000003112 inhibitor Substances 0.000 claims 18
- 230000000291 postprandial effect Effects 0.000 claims 18
- 229940123208 Biguanide Drugs 0.000 claims 16
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 16
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical group C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 16
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 16
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 16
- 229960003834 dapagliflozin Drugs 0.000 claims 16
- 229960003345 empagliflozin Drugs 0.000 claims 14
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 14
- 230000010030 glucose lowering effect Effects 0.000 claims 11
- 238000011287 therapeutic dose Methods 0.000 claims 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 9
- 229940127003 anti-diabetic drug Drugs 0.000 claims 9
- 239000008103 glucose Substances 0.000 claims 9
- 230000003178 anti-diabetic effect Effects 0.000 claims 8
- 230000002195 synergetic effect Effects 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 230000002058 anti-hyperglycaemic effect Effects 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229940000425 combination drug Drugs 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 230000003111 delayed effect Effects 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000008085 renal dysfunction Effects 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 229940096313 sitagliptin 100 mg Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/364,063 | 2019-03-25 | ||
| US16/364,063 US11033544B2 (en) | 2019-03-25 | 2019-03-25 | Low-dose triple combination formulation |
| PCT/IB2020/000214 WO2020194052A1 (en) | 2019-03-25 | 2020-03-25 | Low-dose triple combination formulation |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529208A JP2022529208A (ja) | 2022-06-20 |
| JPWO2020194052A5 true JPWO2020194052A5 (https=) | 2023-04-05 |
| JP2022529208A5 JP2022529208A5 (https=) | 2023-04-05 |
| JP7586830B2 JP7586830B2 (ja) | 2024-11-19 |
Family
ID=72606637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556884A Active JP7586830B2 (ja) | 2019-03-25 | 2020-03-25 | 低用量の三重複合製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11033544B2 (https=) |
| EP (1) | EP3946344A4 (https=) |
| JP (1) | JP7586830B2 (https=) |
| KR (1) | KR20220004027A (https=) |
| CN (2) | CN113924096A (https=) |
| AU (2) | AU2020247542A1 (https=) |
| BR (1) | BR112021018994A2 (https=) |
| CA (1) | CA3134800A1 (https=) |
| MX (2) | MX2021011746A (https=) |
| TW (2) | TW202102209A (https=) |
| WO (1) | WO2020194052A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033544B2 (en) * | 2019-03-25 | 2021-06-15 | The George Institute for Global Health | Low-dose triple combination formulation |
| KR102853692B1 (ko) * | 2021-07-08 | 2025-09-02 | 한미약품 주식회사 | 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제 |
| EP4415723A4 (en) * | 2021-10-12 | 2025-09-03 | Unison Pharmaceuticals Pvt Ltd | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN |
| TR2023001202A1 (tr) * | 2023-02-02 | 2024-08-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇ |
| KR20260000968A (ko) * | 2024-06-26 | 2026-01-05 | 주식회사 종근당 | 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065809A1 (es) * | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| BRPI1008560B1 (pt) * | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| EP3142661B1 (en) * | 2014-05-16 | 2021-10-06 | Astrazeneca AB | Method for suppressing glucagon secretion of an sglt2 inhibitor |
| US20160067217A1 (en) * | 2014-09-09 | 2016-03-10 | ARKAY Therapeutics, LLC | Metabolic syndrome treatment |
| US11033544B2 (en) * | 2019-03-25 | 2021-06-15 | The George Institute for Global Health | Low-dose triple combination formulation |
-
2019
- 2019-03-25 US US16/364,063 patent/US11033544B2/en active Active
-
2020
- 2020-03-25 MX MX2021011746A patent/MX2021011746A/es unknown
- 2020-03-25 CA CA3134800A patent/CA3134800A1/en active Pending
- 2020-03-25 KR KR1020217033517A patent/KR20220004027A/ko active Pending
- 2020-03-25 TW TW109110099A patent/TW202102209A/zh unknown
- 2020-03-25 CN CN202080038969.1A patent/CN113924096A/zh active Pending
- 2020-03-25 TW TW114106241A patent/TW202545526A/zh unknown
- 2020-03-25 AU AU2020247542A patent/AU2020247542A1/en not_active Abandoned
- 2020-03-25 BR BR112021018994A patent/BR112021018994A2/pt unknown
- 2020-03-25 WO PCT/IB2020/000214 patent/WO2020194052A1/en not_active Ceased
- 2020-03-25 CN CN202411820468.5A patent/CN119607213A/zh active Pending
- 2020-03-25 EP EP20779606.1A patent/EP3946344A4/en active Pending
- 2020-03-25 JP JP2021556884A patent/JP7586830B2/ja active Active
-
2021
- 2021-05-11 US US17/317,614 patent/US20210260056A1/en not_active Abandoned
- 2021-09-24 MX MX2024013504A patent/MX2024013504A/es unknown
- 2021-11-15 US US17/527,087 patent/US20220226317A1/en not_active Abandoned
- 2021-11-15 US US17/527,084 patent/US20220226315A1/en not_active Abandoned
- 2021-11-15 US US17/527,085 patent/US20220226316A1/en not_active Abandoned
-
2025
- 2025-09-03 AU AU2025226705A patent/AU2025226705A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3031577T3 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| CN101897696B (zh) | 降糖药物组合物及其用途 | |
| JP2015044875A5 (https=) | ||
| US20230346817A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
| TWI606848B (zh) | 包含格米列汀與美氟明的組合藥物及其製備方法 | |
| US20240366579A1 (en) | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor | |
| CN101181264A (zh) | 一种以盐酸二甲双胍和维格列汀为活性成分的药用组合物及其制备方法、用途 | |
| CN103402506A (zh) | 用于治疗糖尿病的组合 | |
| CN101990427A (zh) | 米格列奈及二甲双胍的复合制剂及其制造方法 | |
| US20180235921A1 (en) | Method of treating hyperglycemia | |
| JPWO2020194052A5 (https=) | ||
| US20260102370A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| JP2024524113A (ja) | シタグリプチン、ダパグリフロジン及びメトホルミンを含む経口用複合錠剤 | |
| JPWO2020194046A5 (https=) | ||
| CN101897697A (zh) | 降糖药物组合物及用途 | |
| CN101897698A (zh) | 含有维格列汀和b族维生素的降糖药物组合物及其用途 | |
| WO2018004498A1 (en) | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation | |
| JP2008189679A (ja) | ２型糖尿病治療用の併用医薬 | |
| CN116157132A (zh) | 一种降低血糖的组合、应用和方法 | |
| CN104840480B (zh) | 二甲双胍/叶酸/维生素b12药物组合物的新用途 | |
| RU2021130142A (ru) | Низкодозовый тройной комбинированный состав | |
| CN101125144A (zh) | 治疗糖尿病的复方药物 | |
| CN1939540B (zh) | 含有胰岛素增敏剂和b族维生素的药物组合物 | |
| CN115192625A (zh) | 一种口服组合物 | |
| RU2021130019A (ru) | Состав низкодозовой тройной комбинации |